Abstract Details

Title Evaluation of School Performance as an Indirect Marker of Cognitive Decline Prior to Diagnosis of Multiple Sclerosis

Topic MS and Related Diseases

Presentation(s) P04 - (-)

Poster/Presentation
Number 119

Objective

Background BACKGROUND: Multiple Sclerosis (MS) encompasses a wide spectrum of clinical manifestations, including cognitive impairment, which is present in up to 70% of patients with advanced disease and 43% of newly diagnosed. It is evidenced even in clinically isolated syndromes (CIS) and isolated radiological syndrome. We decided to study school performance in MS patients, as an indirect marker of impaired premorbid cognitive functions before the first clinical or radiological sign of the disease.

Design/Methods DESIGN/METHODS: School performance was evaluated in the last 3 years of high school in CIS and MS patients, and they were matched with healthy controls by demographic and socioeconomic condition using online questionnaires. We excluded subjects with pathologies during pregnancy and childhood that may affect the SP. We analyzed the distribution of Chi2 and Mann Whitney U statistic according to data type. The variables that showed stronger association with the dependent variable where included to a multiple regression model. Data was analyzed using IBM SPSS Statistics.

Results RESULTS: 113 patients were evaluated, 65 (58%) cases and 48 (42%) controls. 29% (32) were men, mean age 37 + -11 years, with no differences between groups. There were no differences between socioeconomic condition. Worse employment situation was found today in the group of patients (p: 0.021). School drop was higher in the case group (0,02). The averages in mathematics and literature showed lower values in the case group. The values of the group Beck Inventory of cases showed higher values (p: 0.002). On the Fatigue Scale values were also higher in the group of cases (p <0.001). There were no differences in other variables.

Conclusions CONCLUSIONS: MS patients showed lower averages in mathematics and literature; and had higher school drop compared to healthy controls.

Authors/Disclosures
PRESENTER	No disclosure on file
Gisela Zanga	Gisela Zanga has nothing to disclose.
	No disclosure on file
	No disclosure on file
Vladimiro Sinay, MD	No disclosure on file
Orhan Aktas, MD (Neurologische Klinik)	Dr. Aktas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Aktas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen/Horizon. Dr. Aktas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Aktas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubish Tanake. Dr. Aktas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Aktas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AstraZeneca. Dr. Aktas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Aktas has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Aktas has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Aktas has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen/Horizon. The institution of Dr. Aktas has received research support from German Research Foundation. The institution of Dr. Aktas has received research support from German Ministry of Science. The institution of Dr. Aktas has received research support from Neuromyelitis optica Study Group (NEMOS).

��ɫ��

��ɫ��